Jan. 28 at 8:11 PM
$DMAAU ....
$200M...IPO today...some notes.
Our sponsor currently holds 9,857,143 ordinary shares (which were purchased for
$35,000 and which we refer to as “founder shares”), up to 1,285,714 of which are subject to surrender and forfeiture by our sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. Because our sponsor acquired the founder shares at a nominal price, our public shareholders
Once we have completed our IPO, our team will identify potential acquisition targets
The aim will be for this business to have end-to-end capability from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients (“API”)) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients.
Nasdaq listing rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account. TBC..